Literature DB >> 9655997

Prostate carcinoma: clarification through clinical insight and molecular diagnostics.

F J Meyers, R W DeVere White.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9655997      PMCID: PMC1305073     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


× No keyword cloud information.
  5 in total

1.  The impact of informed consent on patient interest in prostate-specific antigen screening.

Authors:  A M Wolf; J F Nasser; A M Wolf; J B Schorling
Journal:  Arch Intern Med       Date:  1996-06-24

2.  Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search.

Authors:  J R Smith; D Freije; J D Carpten; H Grönberg; J Xu; S D Isaacs; M J Brownstein; G S Bova; H Guo; P Bujnovszky; D R Nusskern; J E Damber; A Bergh; M Emanuelsson; O P Kallioniemi; J Walker-Daniels; J E Bailey-Wilson; T H Beaty; D A Meyers; P C Walsh; F S Collins; J M Trent; W B Isaacs
Journal:  Science       Date:  1996-11-22       Impact factor: 47.728

3.  An adjustment to the 1997 estimate for new prostate cancer cases.

Authors:  P A Wingo; S Landis; L A Ries
Journal:  CA Cancer J Clin       Date:  1997 Jul-Aug       Impact factor: 508.702

4.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.

Authors:  A W Partin; M W Kattan; E N Subong; P C Walsh; K J Wojno; J E Oesterling; P T Scardino; J D Pearson
Journal:  JAMA       Date:  1997-05-14       Impact factor: 56.272

5.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.

Authors:  W J Catalona; D S Smith; D K Ornstein
Journal:  JAMA       Date:  1997-05-14       Impact factor: 56.272

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.